Efficacy and Safety of Adalimumab Versus Infliximab in Patients Suffered From Moderate to Severe Active Ulcerative Colitis

Abstract

Objective: Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease of the large intestine, usually involving the rectum. During the last decade, clinical trials have shown adalimumab (ADA) and infliximab (IFX) to be efficacious in inducing and maintaining remission for moderate to severe UC refractory to the conventional therapies. The purpose of this study was to compare the efficacy and safety of ADA and IFX for induction remission in Iraqi patients with moderately to severely active UC.Methods: A total of 50 patients with moderate to severe UC, who were refractory to concurrent treatment with oral corticosteroids and/or immune suppressants, were randomly assigned in 1:1 ratio to receive either ADA (160/80 mg, subcutaneous) or IFX (5 mg/kg, intravenous) during the induction phase (8 weeks). Primary efficacy endpoint was clinical remission at week 8. Secondary efficacy endpoints were the clinical response, mucosal healing, subscores indicative of mild disease (rectal bleeding subscore [RBS], physician's global assessment [PGA] subscore, and stool frequency subscore [SFS]). Partial Mayo score was also evaluated in addition to the inflammatory bowel disease questionnaire (IBDQ). Additional subgroup analysis was based on the Mayo score, extensive colitis, concomitant medications, high sensitivity C-reactive protein (hs-CRP) level, and patient weight at baseline. The safety profile was assessed in all enrolled patients.Results: At week 8, 24% of patients receiving ADA were in clinical remission, compared with 28% on IFX (p>0.05). Clinical response was achieved in 48% of patients receiving ADA and 52% of patients on IFX (p>0.05). Mucosal healing was achieved in 40% of patients receiving either ADA or IFX (p>0.05). For the subscores indicative of mild disease (≤1), the patients % of RBS and PGA was significantly higher within IFX group (p<0.05) while the patients % of SFS was significantly higher within ADA group (p<0.05). The proportion of patients achieving clinical remission based on the partial Mayo score, in addition to IBDQ response index, was not differ significantly between the two groups from week 2 and throughout the study (p>0.05). The patients with higher Mayo score (≥10), higher hs-CRP (≥10 mg/L), and higher weight (≥70 kg) at baseline were associated with reduced remission rates. ADA and IFX treatment were generally well-tolerated and the overall safety profile matched. Conclusion:ADA and IFX were comparable in their effectiveness for inducing clinical remission and response in patients with moderate to severe UC. Both of the biologic agents were well tolerated with an approach safety profile.

Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus

“…Body mass index of 35 or greater (moderate to severe obesity) was a negative prognostic factor for achieving CROT after 1 cycle, independent of dose regimen. Reports on patients with RA and cancer have shown mixed results as to whether BMI affects rituximab efficacy . Relevant clinical factors may include (1) suboptimal lymphoma dosing of rituximab in those with high BMI with use of the Dubois vs the Mosteller formula; (2) the nonlipophilic nature of rituximab, which causes poor penetration through fat tissue; (3) the obesity-associated increase in adipocytokines, which enhance inflammation and promote autoimmunity; and (4) impaired natural killer cell function in obesity, which may decrease rituximab efficacy via antibody-dependent cellular cytotoxicity .…”

Sulfasalazine Attenuates Ulcerative Colitis in Rats via Downregulation of Mirna-31, Metalloproteinase-3 and High Mobility Group Box1

“…Inflammatory bowel disease (IBD) comprises Crohn's disease (CD) and ulcerative colitis (UC) is thought to be triggered by an irregular immune response resulting in a genetically prone host malfunction of the intestinal mucosal barrier against enteric bacteria [1]. The UC is based on the abnormal degradation of the intestinal mucosa due to various reasons; including genetic, environmental, microbial and immune inflammatory mediators [2]. The treatment priorities for IBDs include complication prevention, recovery and rehabilitation of nutritional deficiencies to improve the quality of life of patients.…”